still tavr upsid
upsid look increasingli like tavr growth slow
risk tavr skew posit
earli tavr pascal bridg mitral
replac tricuspid pipelin matur remain
overweight rais pt
tavr guidanc modestli better bottom end assum less share
compress market model project bp share loss
like assum pressur boston lotu low-risk captur
model project high double-digit high single-digit y/i
growth vs reflect momentum stabil upsid factor
bp share compress worth pt tavr growth
momentum consist tavr growth would closer vs
expect trend may play role increment
pipelin perspect manag announc sapien
focu optim safeti efficaci first-in-human complet
pivot enrol less month away timelin reflect
increas regulatori hurdl europ mdr need lock design
perhap conservat given recent issu associ ultra
deliveri system statist better perform unlik numer
improv like paravalvular leak pvl pace
bigger consensu appreci rate low-risk penetr
ultim symptomat sever aortic stenosi sa tavr market size key
structur question manag reiter tavr market estim
increment posit skew prematur evalu
earli tavr asymptomat sever aortic stenosi given emerg data set
like recoveri aha popul increasingli come view
manag introduc concept moder risk see insid detail
meet asymptomat market could equival symptomat
neither popul reflect intermedi term model patient
recoveri younger bicuspid sever treat mechan
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
valv earli tavr patient older mainli tricuspid avers surgeri
larg trial patient given endpoint data
less like
separ studi center around potenti poor surviv rate
patient base moder aortic stenosi neda registri see
indic patient patient
moder sever respect within studi popul
studi conclud moder patient risk similar
poor long-term surviv patient moder aortic stenosi jacc
tmtt guidanc consist top end lower bottom end
still call doubl revenu low end reflect impact pascal
sheath issu could drive flattish trend updat
tmtt revenu tmtt number
pascal go lion share tmtt next year despit
enrol cardioband next major inflect pascal us
approv like case last year tavr potenti
legal headwind pascal includ guidanc trial begin
month uk us may germani juli outlook major
program chang exhibit respect trial pipelin versu
expect line view cardioband remain labor requir
second gener devic drive broader use timelin disclos
expect second impair charg taken mitral develop
unlik tavr linear debat shift tavr
develop mitral tricuspid program go critic
exhibit tmtt trial pipelin updat
surgic structur heart critic surgic outlook
bp lower midpoint last year guidanc outlook reflect greater
develop market tavr eros off-set mix shift higher asp inspiri
growth emerg market growth well late sutrafix
launch harpoon remain track small separ investor
less focus critic import note segment
improv last year driven pt corpor top line
growth assum outlook would slow guidanc versu
model reflect continu growth contribut hemospher well
clearsight foresight contribut
low-risk remain driver still expect lever earn summari
overal revenu line expect vast major tmtt
slowdown off-set stronger critic outlook exhibit
guidanc vs expect guidanc deceler dynam vs
unsurpris model y/i growth versu y/i
margin gross margin expans limit given well telegraph fx
headwind devic tax includ guidanc
manag suggest could off-set portion
potenti impact impli margin flexibl sg leverag
expect flat midpoint line expect
may signal high water mark edward opportun futur
non-op item share count inch higher impli less activ buyback
tax rate better expect higher stock compens
net model ep growth ep upsid tie tavr
perform bp tavr upsid bp margin upsid
ep
equival
prepaid expens ca
net chang work capit
oper
invest intang asset
invest unconsolid affili
proce asset disposit
proce sale busi
proce note receiv
invest
proce issuanc long-term debt
payment long-term debt
proce issuanc short-term debt
payment short-term debt
chang equiti net tax benefit
payment relat ar securit net
financ
effect currenc exchang
tavr market expans continu low risk mitral catalyst
tavr market expans continu low risk mitral catalyst
edward maintain share market share tavr market grow
bn tavr increasingli becom therapi choic even
low risk patient drive penetr global mitral innov
progress faster expect price declin lower expect
price-to-earnings base analysi equival base ep support
price-to-earnings base analysi equival base ep support
tavr market reach global see gradual expans
low risk popul follow low-risk data complement
growth rate higher risk us eu popul ew share declin
time remain market leader coapt result mitral path
forward key edward trial timelin launch need addit clariti
oper leverag acceler long-term margin reach
risk prove bridg far valv durabl remain oustand issu
younger patient still tavr market grow billion
limit low risk intermedi risk traction sapien share slip
traction acceler competit boston off-set
peer
long-term potenti market expans
lower risk patient remain
underappreci drive
out-performance time see market
expans billion said
near term intermedi risk penetr
durabl reflect growth inflect
continu see increment
ebitda margin tavr sale
drive long-term corpor ebit margin
high near term reinvest like
mitral visibl remain low faster
develop could support bull case
project robust mitral opportun
potenti market size aortic
market discount heavili base
case reflect signific uncertainti
futur market
penetr tavr lower risk
popul critic near term
increas visibl structur heart
portfolio key durabl long term growth
risk achiev price
robust commerci traction boston
abbott/st jude long term
potenti pipelin develop failur
mitral space
us european reimburs pressur
price time
price target deriv price-to-earnings base analysi earn
support discount cash flow model assum wacc
termin growth model project tavr market growth billion
drive ebit margin
risk achiev price target includ acceler competit
us near term robust commerci traction boston
abbott/st jude long term ii potenti pipelin develop failur mitral
space market opportun could larger aortic least sever
year away iii reimburs structur us europ could put downward
pressur price time
